There’s no shortage of movers this morning, as shown by the gappers list below. We’ve got a 0.5% gap up working on the Nasdaq. That should be enough to close the February gap and put it around that nice round number of 2,500. Normally I’d expect a number like that to be resistance but with CPI tomorrow and a flood of earnings due this week it could be just another number…
On Today’s Calendar:
- 10:00 — Business Inventories
More Calendars: U.S. Earnings | Conf. Calls | Surprises | IPO | Economic
Potential swing trades:
See one of the recent ‘Chart Reading‘ posts for some potential swing candidates.
Potential day trades:
(From Briefing.com)
Gapping Down
FMD -19.0% (broker note out saying acquisition of SLM may present increased risk to FMD), CPHD -6.1% (mentioned negatively in Barron’s), VRTX -5.5% (announces interim results from PROVE 1 trial of telaprevir; Maxim downgrade to Sell), DGX -2.6% (to acquire AmeriPath in a transaction valued at $2 bln), FCX -2.1% (removed from Conviction Buy List at Goldman).
Gapping Up
M&A: SLM +18.7% (Investor group confirms it will buy SLM for $60/share), Google buys DoubleClick (up in sympathy AQNT +11.5%, VCLK +7.4%, TFSM +7.3%), KPA +7.3% (to be acquired by Apollo Investment for $17.75/share)… Subprime stocks gap higher following FMT news: FMT +26.0% (to sell $2.9 bln of its sub-prime residential loans, also Letter of Intent for sale of most sub-prime residential real estate biz), LEND +7.6%, NFI +6.7%… Other news: PGLA +46.2% (Phase 2 liver cancer trial exceeds efficacy objective), ACEL +26.1% (says preclinical data show it’s Onconase inhibits tumor growth of non-small cell lung cancer, breast cancer cells), GPCB +7.5% (FDA accepts Satraplatin NDA for filing, grants priority review status), ONSM +6.5% (announces that it has been chosen by ADBE as a member of its “Flash Media Solution Provider program”), USU +6.3% (received American centrifuge plant license), DYAX +3.5% (follow-through momentum from Friday’s gap up), UXG +5.0% (follow-through momentum), ARIA +7.0% (files claim against Amgen and Wyeth alleging infringement of patent).
Disclaimer & How I use this list
